353 related articles for article (PubMed ID: 26623729)
1. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.
Wu ZJ; Zhao X; Banaszak LG; Gutierrez-Rodrigues F; Keyvanfar K; Gao SG; Quinones Raffo D; Kajigaya S; Young NS
Int J Oncol; 2018 Apr; 52(4):1209-1223. PubMed ID: 29532865
[TBL] [Abstract][Full Text] [Related]
3. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia.
Vuelta E; Ordoñez JL; Alonso-Pérez V; Méndez L; Hernández-Carabias P; Saldaña R; Sevilla J; Sebastián E; Muntión S; Sánchez-Guijo F; Hernández-Rivas JM; García-Tuñón I; Sánchez-Martín M
CRISPR J; 2021 Aug; 4(4):519-535. PubMed ID: 34406033
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
6. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Rahmani NE; Ramachandra N; Sahu S; Gitego N; Lopez A; Pradhan K; Bhagat TD; Gordon-Mitchell S; Pena BR; Kazemi M; Rao K; Giricz O; Maqbool SB; Olea R; Zhao Y; Zhang J; Dolatshad H; Tittrea V; Tatwavedi D; Singh S; Lee J; Sun T; Steidl U; Shastri A; Inoue D; Abdel-Wahab O; Pellagatti A; Gavathiotis E; Boultwood J; Verma A
Blood Cancer J; 2021 Sep; 11(9):157. PubMed ID: 34548471
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
[TBL] [Abstract][Full Text] [Related]
8. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
García-Tuñón I; Hernández-Sánchez M; Ordoñez JL; Alonso-Pérez V; Álamo-Quijada M; Benito R; Guerrero C; Hernández-Rivas JM; Sánchez-Martín M
Oncotarget; 2017 Apr; 8(16):26027-26040. PubMed ID: 28212528
[TBL] [Abstract][Full Text] [Related]
9. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
[TBL] [Abstract][Full Text] [Related]
10. Efficient genetic manipulation of the NOD-Rag1-/-IL2RgammaC-null mouse by combining in vitro fertilization and CRISPR/Cas9 technology.
Li F; Cowley DO; Banner D; Holle E; Zhang L; Su L
Sci Rep; 2014 Jun; 4():5290. PubMed ID: 24936832
[TBL] [Abstract][Full Text] [Related]
11. Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.
Xie H; Peng C; Huang J; Li BE; Kim W; Smith EC; Fujiwara Y; Qi J; Cheloni G; Das PP; Nguyen M; Li S; Bradner JE; Orkin SH
Cancer Discov; 2016 Nov; 6(11):1237-1247. PubMed ID: 27630126
[TBL] [Abstract][Full Text] [Related]
12. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy.
Liu Y; Zhao G; Xu CF; Luo YL; Lu ZD; Wang J
Biomater Sci; 2018 May; 6(6):1592-1603. PubMed ID: 29725684
[TBL] [Abstract][Full Text] [Related]
13. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
Pellagatti A; Dolatshad H; Valletta S; Boultwood J
Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
[TBL] [Abstract][Full Text] [Related]
14. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
15. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
16. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
17. Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
Huo X; Du Y; Lu J; Guo M; Li Z; Zhang S; Li X; Chen Z; Du X
Mutat Res; 2017 Mar; 797-799():1-6. PubMed ID: 28284774
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
19. β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation.
Qin R; Li K; Qi X; Zhou X; Wang L; Zhang P; Zou L
Br J Cancer; 2014 Jul; 111(3):568-76. PubMed ID: 24937675
[TBL] [Abstract][Full Text] [Related]
20. ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
Valikhani A; Poopak B; Ferdowsi S; Azizi Tabesh G; Ghaffari SH; Saraf Kazeruoni E; Rezaei N; Farshchi A; Amirizadeh N
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e41-e47. PubMed ID: 27640403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
